IP Library › Granted Patent US 11,666,529
Granted Patent B2
US 11,666,529 · App. 15/574,712 · Granted Jun 6, 2023

Use of PRG4 to improve dynamic visual acuity and higher order aberrations

Inventors: Benjamin D. Sullivan (San Diego, CA); Edward R. Truitt, III (Medina, WA)
Assignee: Lubris LLC
A61K9/0048A61K38/1709A61K45/06A61P27/02
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,666,529
App. No.
15/574,712
Granted
Jun 6, 2023
Kind
B2
Abstract

Disclosed are methods involving the therapeutic use of human PRG4 (lubricin) protein, to improve vision, to reduce aberrations such as impaired night vision, halos, and glare, to improve the stability of the tear film, and to homogenize the refractive index of the surface of the eye.

Claims (18)

1. A method of treating a visual aberration due to corneal surface irregularity in an eye of a human patient comprising depositing onto the surface of the eye or of each eye of said patient an amount of 10-100 microliters of an ophthalmically acceptable solution comprising lubricin at a concentration within a range of from 10 μg/mL to 300 μg/mL to form a hydrated gel layer of lubricin across the corneal surface of the eye or of each eye, thereby to alleviate said visual aberration, wherein the visual aberration is selected from the group consisting of diminished night vision, visual halo, visual starburst, loss of static visual acuity, visual glare, and higher order aberrations.

2. The method of claim 1 , wherein the patient has had prior eye surgery selected from the group consisting of cataract surgery, laser in-situ keratomileusis (LASIK), photorefractive keratectomy (PRK), laser epithelial keratomileusis (LASEK), refractive lens exchange (RLE) and presbyopic lens exchange (PRELEX).

3. The method of claim 1 , wherein 15 to 30 microliters of said solution are deposited on the surface of the eye or the surface of each of the eyes of said patient.

4. The method of claim 1 , wherein the solution comprises the lubricin at a concentration within a range of from 50 μg/mL to 200 μg/mL.

5. The method of claim 1 , wherein the solution comprises an ophthalmically acceptable surface active phospholipid selected from the group consisting of L-α-dipalmitoylphosphatidylcholine, phosphatidylcholine, phosphatidylethanolamine and sphingomyelin.

6. The method of claim 1 , wherein the solution comprises a phosphate buffered saline solution comprising at least sodium phosphate and sodium chloride.

7. The method of claim 1 , wherein the solution comprises an ophthalmically acceptable balanced salt solution comprising one or more electrolytes selected from the group consisting of potassium chloride, sodium bicarbonate, potassium bicarbonate, calcium chloride, magnesium chloride, a sodium citrate, hydrochloric acid, and sodium hydroxide.

8. The method of claim 1 , wherein the solution comprises hyaluronate salt or hyaluronic acid.

9. The method of claim 1 , wherein the patient has not been diagnosed with dry eye disease.

10. The method of claim 1 , wherein the lubricin comprises the amino acid sequence of SEQ ID NO:1 less the signal sequence.

11. The method of claim 1 , wherein the depositing lubricin onto the surface of the eye results in essentially immediate amelioration of the visual aberration.

12. The method of claim 1 , wherein the corneal surface irregularity is caused by damage to the corneal epithelium.

13. The method of claim 2 , wherein the cataract surgery, laser in-situ keratomileusis (LASIK), photorefractive keratectomy (PRK), laser epithelial keratomileusis (LASEK), refractive lens exchange (RLE) or presbyopic lens exchange (PRELEX), causes damage to the corneal epithelium, resulting in the corneal surface irregularity.

14. The method of claim 13 , wherein the lubricin comprises the amino acid sequence of SEQ ID NO:1 less the signal sequence.

15. The method of claim 13 , wherein the patient has not been diagnosed with dry eye disease.

16. The method of claim 13 , wherein the depositing lubricin onto the surface of the eye results in essentially immediate amelioration of the visual aberration.

17. The method of claim 13 , wherein the higher order aberration is selected from the group consisting of vertical prism, horizontal prism, astigmatism, defocus, trefoil, vertical coma, horizontal coma, quatrefoil, secondary astigmatism, spherical aberration, an aberration described by higher order Zernike polynomials, micro-aberrations, or macro-aberrations.

18. The method of claim 1 , wherein the higher order aberration is selected from the group consisting of vertical prism, horizontal prism, astigmatism, defocus, trefoil, vertical coma, horizontal coma, quatrefoil, secondary astigmatism, spherical aberration, an aberration described by higher order Zernike polynomials, micro-aberrations, and macro-aberrations.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 15, 2018
From: SULLIVAN, BENJAMIN D.; TRUITT, EDWARD R., III
To: LUBRIS LLC
Reel/Frame 044943/0039 →
Continuity (2)
Provisional Application 62163753 · May 19, 2015
Related Publication 20180140546A1 · May 24, 2018